- Home
- LIPO vs NAOV Comparison
LIPO vs NAOV Comparison
Compare LIPO & NAOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIPO
- NAOV
- Stock Information
- Founded
- LIPO 2005
- NAOV 2003
- Country
- LIPO United States
- NAOV United States
- Employees
- LIPO N/A
- NAOV N/A
- Industry
- LIPO Biotechnology: Pharmaceutical Preparations
- NAOV Industrial Specialties
- Sector
- LIPO Health Care
- NAOV Health Care
- Exchange
- LIPO Nasdaq
- NAOV Nasdaq
- Market Cap
- LIPO 3.1M
- NAOV 2.4M
- IPO Year
- LIPO 2022
- NAOV N/A
- Fundamental
- Price
- LIPO $2.43
- NAOV $4.16
- Analyst Decision
- LIPO
- NAOV
- Analyst Count
- LIPO 0
- NAOV 0
- Target Price
- LIPO N/A
- NAOV N/A
- AVG Volume (30 Days)
- LIPO 160.5K
- NAOV 1.6M
- Earning Date
- LIPO 05-20-2025
- NAOV 05-19-2025
- Dividend Yield
- LIPO N/A
- NAOV N/A
- EPS Growth
- LIPO N/A
- NAOV N/A
- EPS
- LIPO N/A
- NAOV N/A
- Revenue
- LIPO $536,357.00
- NAOV $2,558,000.00
- Revenue This Year
- LIPO N/A
- NAOV N/A
- Revenue Next Year
- LIPO N/A
- NAOV N/A
- P/E Ratio
- LIPO N/A
- NAOV N/A
- Revenue Growth
- LIPO 19.29
- NAOV 12.05
- 52 Week Low
- LIPO $1.97
- NAOV $1.92
- 52 Week High
- LIPO $12.00
- NAOV $16.25
- Technical
- Relative Strength Index (RSI)
- LIPO 46.52
- NAOV 44.93
- Support Level
- LIPO $2.40
- NAOV $2.81
- Resistance Level
- LIPO $2.56
- NAOV $4.56
- Average True Range (ATR)
- LIPO 0.16
- NAOV 0.66
- MACD
- LIPO 0.00
- NAOV -0.19
- Stochastic Oscillator
- LIPO 56.15
- NAOV 31.19
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
About NAOV NanoVibronix Inc.
NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements.